Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus.

Ahmed, Syed Faraz; Sohail, Muhammad Saqib; Quadeer, Ahmed Abdul; McKay, Matthew R

Ahmed, Syed Faraz; Sohail, Muhammad Saqib; Quadeer, Ahmed Abdul; McKay, Matthew R.

Afiliación

Ahmed SF; Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia.
Sohail MS; Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
Quadeer AA; Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
McKay MR; Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia.

Viruses ; 14(9)2022 09 03.

Article en En | MEDLINE | ID: mdl-36146766

Asunto(s)

Monkeypox virus; Vaccinia; Reacciones Cruzadas; Humanos; Monkeypox virus/genética; Vaccinia/prevención & control; Virus Vaccinia/genética

Palabras clave

ACAM2000; Dryvax; MVA-BN; T cells; epitopes; genetic similarity; immunity; monkeypox; neutralizing antibodies; vaccines; vaccinia virus

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_smallpox Asunto principal: Vaccinia / Monkeypox virus Límite: Humans Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: Australia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google